Previous 10 | Next 10 |
Global Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19 Enrollment advancing in Phase 1a trial of AT-752; drug candidate being developed for the treatment of dengue fever BOSTON, May 13, 2021 (GLOBE NEWSW...
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial res...
Atea Pharmaceuticals ([[AVIR]] -1.5%) announces that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.The trial, which is anticipated to enroll about 1,400 non-hospital...
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 i...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CLIR) +15%.Microvision (MVIS) ...
Gainers: ADMA Biologics (ADMA) +25%, Brooklyn ImmunoTherapeutics (BTX) +23%, Clover Health Investments (CLOV) +15%, Neptune Wellness Solutions (NEPT) +12%, Akouos (AKUS) +11%.Losers: Protalix BioTherapeutics (PLX) -40%, Benitec Bioph...
Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...
Gainers: Aesthetic Medical International (AIH) +14%, Acorda Therapeutics (ACOR) +13%, Outlook Therapeutics (OTLK) +12%, Organovo (ONVO) +12%, Asensus Surgical (ASXC) +11%.Losers: Atea Pharmaceuticals (AVIR) -7%, Inotiv NOTV -7%, Lava Ther...
Image source: The Motley Fool. Biota Pharmaceuticals (NASDAQ: AVIR) Q4 2020 Earnings Call Mar 30, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biota Pharmaceuticals (AVIR) Q4 2020 Earnings Call Transcript
Atea Pharmaceuticals (AVIR): FY GAAP EPS of -$0.51 beats by $0.94.Revenue of $48.63MPress Release For further details see: Atea Pharmaceuticals EPS beats by $0.94
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...